0001387131-20-003130.txt : 20200324 0001387131-20-003130.hdr.sgml : 20200324 20200324075318 ACCESSION NUMBER: 0001387131-20-003130 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200320 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200324 DATE AS OF CHANGE: 20200324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TherapeuticsMD, Inc. CENTRAL INDEX KEY: 0000025743 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870233535 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-00100 FILM NUMBER: 20736629 BUSINESS ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-961-1900 MAIL ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: AMHN, Inc. DATE OF NAME CHANGE: 20090930 FORMER COMPANY: FORMER CONFORMED NAME: CROFF ENTERPRISES INC DATE OF NAME CHANGE: 19970915 FORMER COMPANY: FORMER CONFORMED NAME: CROFF OIL CO DATE OF NAME CHANGE: 19920703 8-K 1 txmd-8k_032020.htm CURRENT REPORT
0000025743 false 0000025743 2020-03-20 2020-03-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): March 20, 2020

 

TherapeuticsMD, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada   001-00100   87-0233535

(State or Other Jurisdiction of Incorporation)

  

(Commission File Number)

   (IRS Employer Identification No.)

 

  951 Yamato Road, Suite 220
Boca Raton, FL 33431
  (Address of principal executive office) (zip code)

 

Registrant’s telephone number, including area code: (561) 961-1900

 

Not Applicable
(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, par value $0.001 per share TXMD The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company     ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

 

   
 

 

 Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(b)

On and effective as of March 20, 2020, each of Dr. Brian Bernick, Mr. John C.K. Milligan, IV and Mr. Nicholas Segal resigned from the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), and any committees thereof. None of Dr. Bernick or Messrs. Milligan or Segal resigned as the result of any disagreement with the Company. Following their resignations from the Board, Mr. Milligan, the Company’s President and Secretary, and Dr. Bernick, a Co-Founder of the Company, will continue to serve as full-time employees of the Company.

(d)

On and effective as of March 20, 2020, the Board appointed each of Paul Bisaro and Dr. Gail Naughton as directors to fill two of the vacancies created by the resignations of Messrs. Bernick, Milligan and Segal from the Board. Mr. Bisaro and Dr. Naughton will serve until the Company’s 2020 Annual Meeting of Stockholders and until his or her respective successor is duly elected or appointed or his or her earlier death or resignation. As of March 20, 2020, following the aforementioned resignations and appointments, there were 11 authorized directors of the Company with one vacancy.

The Board has determined that each of Mr. Bisaro and Dr. Naughton is independent under the rules of the Nasdaq Global Select Market. Mr. Bisaro and Dr. Naughton have not yet been appointed to any committees of the Board. As directors of the Company, Mr. Bisaro and Dr. Naughton will each receive compensation in the same manner as the Company’s other non-employee directors, described in the section entitled “Director Compensation” in the Company’s 2019 Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2019.

There are no arrangements or understandings between either Mr. Bisaro or Dr. Naughton and any other person pursuant to which such persons were appointed as directors of the Company. Other than as described in this Current Report on Form 8-K, since the beginning of the Company’s last fiscal year, the Company has not engaged in any transactions, and there are no proposed transactions, or series of similar transactions, in which either Mr. Bisaro or Dr. Naughton was or is to be a participant and in which any related person had a direct or indirect material interest in which the amount involved exceeds or exceeded $120,000.

Item 7.01Regulation FD Disclosure.

 

On March 24, 2020, the Company issued a press release announcing the resignations of Dr. Bernick and Messrs. Milligan and Segal from the Board and the concurrent appointments of Mr. Bisaro and Dr. Naughton to the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. 

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits 

Exhibit Index

 

Exhibit
Number

  

Description of Exhibit

     
99.1   Press Release from TherapeuticsMD, Inc., dated March 24, 2020, entitled “TherapeuticsMD Strengthens Board with Appointment of Industry Leaders”.
104   Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

 

   
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 THERAPEUTICSMD, INC.
     
Date: March 24, 2020 By: /s/ Daniel A. Cartwright
     

Daniel A. Cartwright

Chief Financial Officer

 

 

   

 

 EX-99.1 2 ex99-1.htm PRESS RELEASE

 

THERAPEUTICSMD, INC. 8-K

 

Exhibit 99.1

 

 

FOR IMMEDIATE RELEASE

 

 

TherapeuticsMD Strengthens Board with Appointment of Industry Leaders
– Paul Bisaro and Gail Naughton, Ph.D., Appointed as Independent Directors –

 

BOCA RATON, Fla. – March 24, 2020 – On behalf of the Board of Directors of TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, Chairman Tommy G. Thompson today announced the appointments of Paul Bisaro and Gail Naughton, Ph.D., to the Company’s Board of Directors. The appointments fill two of the vacancies created by the resignations from the Board of Brian Bernick, M.D., John C.K. Milligan, IV and Nicholas Segal. Dr. Bernick will continue to serve as a Co-Founder of TherapeuticsMD on a full-time basis, supporting the Company’s outreach with healthcare providers. Mr. Milligan will continue to serve as the President of TherapeuticsMD on a full-time basis, leading the Company’s infrastructure and critical operations.

 

“We are very pleased to add Paul and Gail as the newest independent directors to our Board. Each has a wealth of experience as both directors and members of senior management at successful organizations,” said former -Governor and Secretary of Health and Human Services, Thompson. “This is an exciting time in our company’s growth and development, and we believe that Paul and Gail’s respective skill sets will complement our recent transformation to a commercial organization.”

 

“On behalf of the TherapeuticsMD Board of Directors, I would like to thank Brian, John and Nick for their service to our company,” said Thompson. “Brian’s passion for innovation and persistence in solving patient needs are the reasons we have world-class products. Brian will continue to serve as our Co-Founder and play a key role in our outreach to healthcare providers. John’s commitment and can-do attitude built the infrastructure and critical operations that our Company has today. John will continue to serve as our President and lead our infrastructure and critical operations. Nick and his family were among our early investors and without their vision and commitment we would not be where we are today. We are excited to welcome Paul and Gail to the TherapeuticsMD Board of Directors. Each of them brings significant experience that we believe will activate our next stage of growth.”

 

“I am very pleased and honored to be joining the TherapeuticsMD Board of Directors,” said Mr. Bisaro. I believe TherapeuticsMD’s portfolio of differentiated products meets many of the significant unmet needs facing women today. In addition, I believe the Company’s vitaCare platform – which was created to remove the hassle and lack of visibility that patients often face when dealing with their insurance coverage, reimbursement and supply – is a unique capability that supports TherapeuticsMD’s patients. I look forward to working with the Board and management team to use these assets to help our patients while continuing to focus on creating long-term value for our shareholders.”

 

Mr. Bisaro is an accomplished global business leader with more than 25 years of generic and branded pharmaceutical experience, and a track record of driving company growth through operational execution and corporate transformation. He has served as Executive Chairman of Allergan, plc (formerly Actavis, plc), President, Chief Executive Officer and a member of the Board of Directors of Actavis (and its predecessor firm Watson Pharmaceuticals, Inc.), Executive Chairman of Amneal Pharmaceuticals, Inc., and President, Chief Executive Officer and a member of the Board of Directors of Impax Laboratories, Inc. until its acquisition by Amneal. He also served as President, Chief Operating Officer and a member of the Board of Directors of Barr Pharmaceuticals, Inc.

 

“I am honored and delighted to be joining the Board of Directors of TherapeuticsMD. The directors and executives have created innovative products that are poised to greatly enhance women’s health and I share in their vision in continuing to develop solutions that will be transformative to healthcare worldwide,” said Dr. Naughton.

 

Dr. Naughton is an accomplished life sciences executive and researcher. Dr. Naughton founded two regenerative medicine companies and is the holder of more than 105 U.S. and foreign patents. She served as the Dean of the College of Business at San Diego State University from 2002-2011. Her current venture, Histogen, is focused on the development of novel solutions based on the products of cells grown under simulated embryonic conditions. She currently serves as Histogen’s Chief Scientific Officer and Chief Business Development Officer and is the inventor of its core technology. Dr. Naughton has brought several tissue engineered products to market including a product for severe burns (TransCyte), a dermal replacement for diabetic ulcers (Dermagraft), an aesthetic dermal filler (Cosmederm/Cosmeplast) and SkinMedica’s TNS product for skin care. Dr. Naughton has been extensively published and is a frequent speaker in the field of tissue engineering and regenerative medicine. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering.

 

“We are thankful to each of Brian, John and Nick for their years of service on our Board and look forward to continuing to work with Brian and John as key members of our leadership team,” concluded TherapueticsMD Chief Executive Officer Robert G. Finizio. “As TherapeuticsMD looks to the future, adding two seasoned experts in Mr. Bisaro and Dr. Naughton to the Board while continuing to utilize two proven performers in Dr. Bernick and Mr. Milligan, is an ideal scenario.”

 

   
 

 

About TherapeuticsMD

 

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

 

Forward-Looking Statements

 

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, BIJUVA® and its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility, including the conditions to draw an additional tranche thereunder and whether the lender will make such tranche available; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; whether the FDA will approve the efficacy supplement for the lower dose of BIJUVA; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at it website: www.therapeuticsmd.com/pressreleases.aspx.

 

# # #

 

Investor Contact

Nichol Ochsner

Vice President, Investor Relations

561-961-1900, ext. 2088

Nochsner@TherapeuticsMD.com

 

   

 

 GRAPHIC 3 txmd_logo.jpg GRAPHIC begin 644 txmd_logo.jpg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end EX-101.SCH 4 txmd-20200320.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 5 txmd-20200320_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 6 txmd-20200320_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name ZIP 7 0001387131-20-003130-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-20-003130-xbrl.zip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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} JSON 10 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "txmd-8k_032020.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "txmd-8k_032020.htm" ] }, "labelLink": { "local": [ "txmd-20200320_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "txmd-20200320_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "txmd-20200320.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 60, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "TXMD", "nsuri": "http://therapeuticsmd.com/20200320", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "txmd-8k_032020.htm", "contextRef": "From2020-03-20to2020-03-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://therapeuticsmd.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "txmd-8k_032020.htm", "contextRef": "From2020-03-20to2020-03-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://therapeuticsmd.com/role/Cover Cover Cover 1 false false All Reports Book All Reports txmd-8k_032020.htm ex99-1.htm txmd-20200320.xsd txmd-20200320_lab.xml txmd-20200320_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( *@^>% ?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ J#YX4"?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " "H/GA0.>0V;N\ K @ $0 &1O8U!R;W!S+V-O M&ULS9+/:L,P#(=?9?B>R(GW!TR:2\M.&PQ6V-C-V&IK&L?&UDCZ]DN\ M-F5L#["CI9\_?0(U.DCM([Y$'S"2Q70SNJY/4H<5.Q %"9#T 9U*Y93HI^;. M1Z=H>L8]!*6/:H]0$T=@U< 3.,,+KT74"S$'/U3VSN #LGQV27U# ,Y2!R;MJA M@O?GI]>\;F'[1*K7./U*5M(IX(I=)K^)]6;[R-J:U[S@HJAOM_Q!W@G)Q&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " "H/GA0GP";";8" !?# & 'AL+W=O"U%Q5M5(K15>U_>TD3D 'F-I. M$4=ZG>="6$B=[;IM/;N#*F?TX2?:Q$R_63[$5G MGYRE:KFQ0W5)=*\$/PVDMDD@39=)R^LN+HMA;J_*0EY-4W=BKR)];5NN_NU$ M(^_;F,4?$Z_UI3)N(BF+GE_$3V%^]7ME1\EP=(1 M!L3O6MSUPWWDMG*0\LT-OIVV<>I6)!IQ-*X$MY>;>!%-XRK9=?R=BL:SIB,^ MWG]4_S)LWF[FP+5XDQF%AI5_YH:7 MA9+W2(TOO^?.8_8,]MT3P*H9G=O':SM[*M$ANKLR$V(T(>$"P&9'8VK, MD (PT+,'.M#TC*1G SU_H&?>^C BIP5R4B!'](4G@!%+6F!!"BP0?>4)8,2: M%EB2 DM$WW@"&,%26F%%*JPPGWD2!"3@\YJ46&.^;S0!"3B](24VF.];34 " M7K.4CE.**_AV4YB X2P06H8K^)X3& B8SNCD,L 5?-LI3,!W1@>&8XS(/>X41GR'T" M$W*?CCW#H<*1SOXLIS,)321Z.AN[H_8.K2]WIZ""-/64.9\&SE$;8>NF3 M771E3_OSH!%GXVY7]EZ-1]YQ8&0_'>>3^3]%^1]02P,$% @ J#YX4)68 M_.B# @ D 8 !0 !X;"]S:&%R9613=')I;F=S+GAM;)55;6_:,!#^W/V* M$]J'5@+R0J'M1)$8+U55H*Q$>]4^F.1(K"5V9CLM_/M=8$533#8M4J3$=_?X M>KX MKMMS,L9% PK!?Q8XDH4PMXW+7F/0UWS0-X.1?$;5=\R@[Y0+A\4Y4VWPW2:] MOELU[B/@VW"MC6*A^5ZUCV589"@,!+L'-V=DK)1!AN=C#E*<*BR-9V(ES7:]'KUH4^8I DK0ZD%J6!?/8JXRLB2 MNOA8 S:,(H5:-U\_8,8%PJ.P$&ZZ'GQA5,D2GB2+_@LN>)%5_U7!B;5?>^I' MH%'Y1^H"^2*JON]ER.")*%F6*LHQ24LEG[D(+7G3V;\@EE(;JH"O/#^9X4[G MLN-9S;A'H)X_&7+>[7D7U<49:4IAF4A15_4W/:_EW=A%_TEQ8U#05EE&\^10 M9-I*O$QYR T7,:%ID>U)/"GE1FT)C3$V5%UAB](WN]*Z32=.7D&?PF1Q3Y/UBML'9^2])[N$^;!%RF-J\%M M91*Z0D4FH0ERG&B[,**Q+ 01C?)&+7AK-)\UK#,6P]-6(.5+.,*OS17WV)"8 M\[$.QT""BM7TJU[,>%S1"?Q'MLA]H+V_B998<3'X8?"KT;/_;3 (SPX:,<[^ MV&SU/3NW5D[OI6BU@KB6WQ9,;BQ89'RM0SKCQ*OG"S>E\@ X2B[@4%1'Y+OC M]@PCKK=I;&[5G/Z'FO_V/K>@P7%Y%.VO_K^\RW^BF"W=>&%S.F7\/#*JS[9^]33(R_] W[%[^?6T/!!XG-8\1S,Z6Y_"B]- M\K!EG3>*G.[V9ZC%H-[.!?>_1/$#4$L#!!0 ( *@^>% P _>^-P$ "(" M / >&PO=V]R:V)O;VLN>&ULC5'!;L(P#/V5*A^P%K0A#5$NH&U(TX;& MQ#UM76J1Q)438./KYP1UL-M.CI_MY^>7V8EX7Q'MLR]KG"]5%T(_S7-?=V"U MOZ,>G%1:8JN#I+S+?<^@&]\!!&OR<5%,F0X]NEVI1BIKD7W8Q-VITZ)#BV=H M4N8[.KT0XYE1,:+[B<6J\YBR'QC.\?1H]B MZ<&8A6#O[I5TXH\ M *A0V$LZ&8O:3RKC>LG^Z&JPLFAEC1"'X17FP?+)K M=$U'AZS@>S'G10R/'1Y?,5'W])=9SUZ",*V'O\E$_37 ZM=E7U!+ P04 M" "H/GA0"X_8 R$! !7! $P %M#;VYT96YT7U1Y<&5S72YX;6RU5$U/ MPS ,_2M3KVC-X, !;;L 5Y@$?R D;ALU7[*]T?U[W&Y#8BIB:-LEB?/L]UX2 M*_/W;0::=,%'6A0- MBVD1[1#K=$Y8(?LBAQF6ZD81B\MP) M"\G>HA"4"G6"PG%A'TO=ZP80G85_64M5Y0S89-9!2DK*"-I2 \#!E]1H!/O& MZ&*]][O2R"\Z"+'JO/J14%[/!V\]C!L8D$LJL[0%C$D-P&Z\/4OPT TF(4PS M"HKL1HXGEE:"DNH3+WE$Z%O'@CU)7*BO]["?"=MA/7;AWR"I83KOUO]H=)G+ MH%W\S0V;N\ K @ $0 @ &9 0 M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " "H/GA0F5R<(Q & "<)P M$P @ &W @ >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 M ( *@^>%"? )L)M@( %\, 8 " ?@( !X;"]W;W)K M&PO&PO% P _>^-P$ "(" / M " 9L0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " "H/GA0_\ F"+T M "% @ &@ @ '_$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " "H/GA0"X_8 R$! !7! $P M@ 'T$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "@ * ( " !&% " ! end XML 14 txmd-8k_032020_htm.xml IDEA: XBRL DOCUMENT 0000025743 2020-03-20 2020-03-20 iso4217:USD shares iso4217:USD shares 0000025743 false 8-K 2020-03-20 TherapeuticsMD, Inc. NV 001-00100 87-0233535 951 Yamato Road Suite 220 Boca Raton FL 33431 (561) 961-1900 Not Applicable false false false false Common Stock, par value $0.001 per share TXMD NASDAQ false XML 15 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover
Mar. 20, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 20, 2020
Entity File Number 001-00100
Entity Registrant Name TherapeuticsMD, Inc.
Entity Central Index Key 0000025743
Entity Tax Identification Number 87-0233535
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 951 Yamato Road
Entity Address, Address Line Two Suite 220
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33431
City Area Code (561)
Local Phone Number 961-1900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TXMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Information, Former Legal or Registered Name Not Applicable